AD

Pfizer says COVID treatment Paxlovid fails to prevent infection of household members

Logo Nasdaq
Nasdaq
By Reuters

By Deena Beasley

AD
AD

April 29 (Reuters) - Pfizer Inc PFE.N on Friday said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone infected with the virus.

The trial enrolled 3,000 adults who were household contacts exposed to an individual who was experiencing symptoms and had recently tested positive for COVID-19. They were either given Paxlovid for five or 10 days or a placebo.

Those who took the five-day course were found to be 32% less likely to become infected than the placebo group. That rose to 37% with 10 days of Paxlovid. However, the results were not statistically significant and thus possibly due to chance.

Pfizer said safety data in the trial was consistent with previous studies, which had shown the pills to be nearly 90% effective at preventing hospitalization or death in COVID patients at high risk of severe illness when taken for five days shortly after symptom onset.

While we are disappointed in the outcome of this particular study, these results do not impact the strong efficacy and safety data weve observed in our earlier trial for the treatment of COVID-19 patients, Pfizer Chief Executive Albert Bourla said in a statement.

Continue read on nasdaq.com

AD
Logo Nasdaq
Adds details April 4 (Reuters) - Pfizer Inc PFE.N said on Monday it made 6 million courses of its antiviral COVID-19 pill Paxlovid in the first quarter,...

Logo Nasdaq
By Natalie Grover April 21 (Reuters) - The World Health Organization (WHO) on Thursday endorsed the use of Pfizer Inc's oral COVID-19 antiviral treatment in...

Logo Nasdaq
MarketsBy Reuters19 Apr
By Michael Erman April 19 (Reuters) - Worldwide demand for Pfizer Inc's PFE.N oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to...

Logo Indiatimes
The World Health Organization said Friday it strongly recommended Pfizer 's Covid-19 antiviral pill Paxlovid for patients with milder forms of the disease...

Logo Indiatimes
The Indian Council of Medical Research's ( ICMR ) National Task Force on Covid-19 is likely to meet this week to review data available on antiviral drug...

Logo Nasdaq
By Nancy Lapid April 11 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to...

Logo Nasdaq
TAIPEI, April 11 (Reuters) - Taiwan has ordered 700,000 units of Pfizer Inc's PFE.N anti-viral COVID-19 pill Paxlovid, its health minister said on Monday,...

Logo Benzinga
Shionogi & Co., Ltd. (hereafter Shionogi) today announced new results from two late-breaking presentations of S-217622 at the 32nd European Congress of...

Logo Benzinga
With a prescription from their healthcare provider, Rite Aid customers have increased access to Paxlovid and Molnupiravir Rite Aid RAD today announced that...

Logo Nasdaq
By Nancy Lapid April 4 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to...

Logo Indiatimes
India's drug regulator approved antiviral medication Paxlovid on Thursday for restricted emergency use against Covid-19 amid rising infections in the...

Logo Nasdaq
(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) announced FDA has cleared the Investigational New Drug application to support a phase 2 clinical trial...

Logo CNN
Washington (CNN)The Biden administration has secured the purchase of 20 million treatment courses of Paxlovid, Pfizer's antiviral Covid-19 pill, a senior...

Logo Investing.com
MarketsBy Reuters 4 Apr
Reuters. Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients...

Logo Indiatimes
After Hetero Labs, Hyderabad-based Optimus Pharma has got close to launching in the country the generic version of Pfizer 's antiviral drug Paxlovid, which...

Logo Benzinga
Proposed acquisition strengthens Pfizer's capabilities in infectious disease research and development with a complementary strategy to help improve patient...

Logo Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus WHO Backs Pfizer's Oral COVID Antiviral Therapy For...

Logo Nasdaq
By Ahmed Aboulenein WASHINGTON, April 26 (Reuters) - U.S. President Joe Biden's administration is aiming to expand access to COVID-19 oral antiviral...

Logo WJXT
WASHINGTON President Joe Biden and his administration want Americans and their doctors to know that the country has an ample supply of the life-saving...

Logo Benzinga
The Biden administration is expected to outline plans for easier access to COVID-19 treatments. According to some health leaders and patient advocates, oral...